Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Atrial Fibrillation Drugs Market

Atrial Fibrillation Drugs Market Size

  • Report ID: GMI3253
  • Published Date: Apr 2019
  • Report Format: PDF

Atrial Fibrillation Drugs Market Size

Atrial Fibrillation Drugs Market size was valued at USD 13 billion in 2018 and is expected to witness 3% CAGR from 2019 to 2025.


Atrial Fibrillation Drugs Market

To understand key trends  
Download Free Sample

Atrial fibrillation drugs market is expected to witness lucrative growth over the forecast period. Increasing rate of geriatric population coupled with rising prevalence of valvular diseases will augment the market growth. Moreover, increasing rate of population suffering from diabetes is another factor fueling the growth of atrial fibrillation drugs market. Increasing prevalence of cardiovascular diseases in emerging regions owing to rise in sedentary lifestyle and increasing habit of binge eating will fuel adoption rates in developing as well as certain developed countries.

However, drug side effects will be one of the major reasons hindering the adoption rates in few developing and under-developed countries. Drug side effects such as severe bleeding, tiredness, etc. will continue to hamper market growth over the forecast timeframe. Also, lack of awareness about recent medical drug therapies for the treatment of atrial fibrillation in certain emerging regions might hamper the market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of atrial fibrillation drugs exceeded USD 13 billion in 2018.

The industry share of atrial fibrillation drugs is expected to witness 3% CAGR from 2019 to 2025.

Occurrence of cardiovascular diseases in North America and Europe and rising demand for unmet atrial fibrillation drug therapy are slated to fuel the demand for atrial fibrillation drugs.

Increase in the number of patients suffering from atrial fibrillation needing restoration of sinus rhythm and upsurge in geriatric population are triggering the use of atrial fibrillation drugs in heart rhythm control.

Rampant valvular diseases in the U.S. and the palpable presence of leading drug manufacturing companies including Bristol-Myers Squibb and Johnson & Johnson are encouraging stakeholders to invest in North America.

Occurrence of significant number of atrial fibrillation drug therapies in hospitals and increase in supply agreements between hospitals and manufacturing firms have led to the use of atrial fibrillation drugs in hospitals.

Atrial Fibrillation Drugs Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies
Immediate Delivery Available

Premium Report Details

  • Base Year: 2018
  • Companies covered: 10
  • Tables & Figures: 728
  • Countries covered: 40
  • Pages: 350
 Download Free Sample